TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33446921

Group type: EXPERIMENTAL
Intervention: Lacto-N-neotetraose
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Sialyllacto-N-tetraose c (LSTc)
Number of subjects: 370

Group type: COMPARATOR
Intervention: 3'-sialyllactose and LSTc
Number of subjects: 370

Group type: COMPARATOR
Intervention: Lewis or secretor-dependent HMOs like 2'-fucosyllactose
Number of subjects: 370
Study: 33447520

Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33447870

Group type: EXPERIMENTAL
Intervention: Group consultation prior to surgery for colorectal cancer
Number of subjects: 124
Study: 33447904

Group type: EXPERIMENTAL
Intervention: Pipeline embolization device (PED)
Number of subjects: 1171
Study: 33448002

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy (LH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abdominal hysterectomy (AH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oophorectomy
Number of subjects: 0
Study: 33448286

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT) emphasizing parent-led infant-directed singing during NICU hospitalization and across 3 months post-discharge
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 3
Study: 33448731

Group type: EXPERIMENTAL
Intervention: Daily Truvada (HIV preexposure prophylaxis)
Number of subjects: 255
Study: 33448881

Group type: EXPERIMENTAL
Intervention: Exome sequencing
Number of subjects: 98
Study: 33448893

Group type: EXPERIMENTAL
Intervention: Ofatumumab and bendamustine followed by ofatumumab maintenance
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Ofatumumab maintenance after induction therapy
Number of subjects: 49
Study: 33448932

Group type: EXPERIMENTAL
Intervention: SwQoR-LA (Quality of Recovery Scale) via mobile app (RAPP)
Number of subjects: 107
Study: 33449073

Group type: EXPERIMENTAL
Intervention: Hispanic women
Number of subjects: 158814

Group type: COMPARATOR
Intervention: Non-Hispanic Whites
Number of subjects: 158814
Study: 33449193

Group type: EXPERIMENTAL
Intervention: Direct composite restorations placed under general anesthesia
Number of subjects: 101
Study: 33449428

Group type: EXPERIMENTAL
Intervention: Targeted Drug Delivery (TDD) for chronic nonmalignant pain
Number of subjects: 4646
Study: 33449578

Group type: EXPERIMENTAL
Intervention: Cognitive functioning interventions for PLWH
Number of subjects: 0
Study: 33449605

Group type: EXPERIMENTAL
Intervention: Verification phase (VER) after graded exercise test (GXT)
Number of subjects: 33
Study: 33449813

Group type: EXPERIMENTAL
Intervention: Eprenetapopt (APR-246) in combination with azacitidine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Azacitidine
Number of subjects: 55
Study: 33449824

Group type: EXPERIMENTAL
Intervention: Visual inspection screening (intervention group)
Number of subjects: 96116

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 96116
Study: 33450010

Group type: EXPERIMENTAL
Intervention: Multi-electrode radiofrequency balloon catheter (RFB) for pulmonary vein isolation (PVI)
Number of subjects: 85
Study: 33450184

Group type: EXPERIMENTAL
Intervention: Surgery for mesothelioma after radiotherapy (SMART) protocol including 25 Gy IMRT followed by extrapleural pneumonectomy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Surgery for mesothelioma after radiotherapy (SMART) protocol
Number of subjects: 96
Study: 33450367

Group type: EXPERIMENTAL
Intervention: Moderate/severe white matter hyperintensities (WMHs), n=86 (41%)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Endovascular treatments in individuals with cerebral infarct
Number of subjects: 210
Study: 33450703

Group type: EXPERIMENTAL
Intervention: Higher levels of Th1 cells at baseline (CD45RA- CCR6- CXCR3+ CCR4-)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Higher levels of Th2 cells (CD45RA- CCR6- CXCR3- CCR4+)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Multimarker score of higher levels of Th1 cells and CD8+ central memory T-cells
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High TIM3 expression on T-cells
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Higher levels of phenotypically naive (CCR7+CD45RA+) and effector memory (CCR7-CD45RO+) CD8+ T-cells
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lower levels of Th2 cells
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Multimarker score of higher CD19+ and CD8+ cells
Number of subjects: 28
Study: 33450821

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33451297

Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant (DEX implant)
Number of subjects: 35
Study: 33451313

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 1484

Group type: EXPERIMENTAL
Intervention: Mask related side-effects (MRSEs) questionnaires
Number of subjects: 1484
Study: 33451780

Group type: EXPERIMENTAL
Intervention: Sci-B-Vac® (tri-antigenic recombinant Hepatitis B vaccine)
Number of subjects: 91
Study: 33451977

Group type: EXPERIMENTAL
Intervention: TTI-621 (SIRPα-IgG1 Fc)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: TTI-621 combined with rituximab
Number of subjects: 164
Study: 33452195

Group type: EXPERIMENTAL
Intervention: Hospitalised children
Number of subjects: 12500

Group type: EXPERIMENTAL
Intervention: All children
Number of subjects: 12500
Study: 33452634

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 103
Study: 33453199

Group type: EXPERIMENTAL
Intervention: Tele-clinic visits using parentally acquired vital signs and focused echocardiographic images.
Number of subjects: 15

Group type: COMPARATOR
Intervention: On-site clinic visits (control group).
Number of subjects: 15
Study: 33453294

Group type: EXPERIMENTAL
Intervention: Hyperglycemic patients with high levels of Prevotella and TMAO in coronary thrombus
Number of subjects: 146

Group type: COMPARATOR
Intervention: Normoglycemic patients with low levels of Prevotella and TMAO in coronary thrombus
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Patients with hyperglycemia (≥140 mg/dl)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Patients with normal glucose levels (<140 mg/dl)
Number of subjects: 146
Study: 33454126

Group type: EXPERIMENTAL
Intervention: Severe migraine participants
Number of subjects: 23
Study: 33454128

Group type: EXPERIMENTAL
Intervention: Phosphate measurement in ICU patients
Number of subjects: 909

Group type: COMPARATOR
Intervention: Treatment protocol for phosphate repletion
Number of subjects: 909

Group type: COMPARATOR
Intervention: Phosphate repletion in HypoP patients
Number of subjects: 909
Study: 33454260

Group type: EXPERIMENTAL
Intervention: Topological Data Analysis (TDA) of quantitative coronary plaque characteristics on coronary CTA
Number of subjects: 1264

Group type: EXPERIMENTAL
Intervention: Group A (identified by TDA)
Number of subjects: 1264

Group type: EXPERIMENTAL
Intervention: Patient similarity network by TDA
Number of subjects: 1264
Study: 33454291

Group type: EXPERIMENTAL
Intervention: Indigo aspiration system
Number of subjects: 119
Study: 33454601

Group type: EXPERIMENTAL
Intervention: MOG-ab testing in AQP4-ab-negative patients
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Optic neuritis as a symptom
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Neuroimaging findings
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Immunosuppressant treatments
Number of subjects: 67
Study: 33454817

Group type: EXPERIMENTAL
Intervention: Antibiotic-first therapy
Number of subjects: 318

Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 318
Study: 33455802

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%, 200 ml (400 mg) injected peri-articularly in each knee
Number of subjects: 28
Study: 33455902

Group type: EXPERIMENTAL
Intervention: HeartBot app intervention for 21 days, 30 minutes daily.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Waitlist control group (no intervention).
Number of subjects: 88
Study: 33455928

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs)
Number of subjects: 0
Study: 33458803

Group type: EXPERIMENTAL
Intervention: Ultra Rapid Lispro (URLi)
Number of subjects: 893

Group type: COMPARATOR
Intervention: Lispro
Number of subjects: 893
Study: 33459029

Group type: EXPERIMENTAL
Intervention: Regularized logistic regression classifier based on 73 hybrid ECG features
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Subset of 73 hybrid ECG features
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Metrics of nondipolar electrical dispersion, ventricular activation time, QRS and T axes and angles, principal component analysis ratio of ECG waveforms
Number of subjects: 1244
Study: 33459278

Group type: EXPERIMENTAL
Intervention: Ghya Bharari Ekatra (GBE) intervention delivered over 6 weekly sessions by lay peer educators; included components on relationship quality, resilience, communication, self-esteem, sexual communication, and norms around IPV.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group receiving information on IPV support services alone.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GBE intervention
Number of subjects: 40
Study: 33459600

Group type: EXPERIMENTAL
Intervention: Standalone text messaging obesity intervention (Charge)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Text messaging components (various experimental conditions)
Number of subjects: 32
Study: 33459599

Group type: EXPERIMENTAL
Intervention: Tobacco Heating System (THS)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 172
Study: 33460002

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Entecavir + Thymosin-alpha1 (ETV + Thy-α1)
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Lamivudine + Adefovir (LAM + ADV)
Number of subjects: 937
Study: 33460016

Group type: EXPERIMENTAL
Intervention: Orally administered semaglutide 7 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orally administered semaglutide 14 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dulaglutide 0.75 mg
Number of subjects: 0
Study: 33460048

Group type: COMPARATOR
Intervention: Immediate-release methylphenidate
Number of subjects: 497
Study: 33461041

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV)
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) in ULD subgroup
Number of subjects: 853
Study: 33461307

Group type: EXPERIMENTAL
Intervention: 3 g/day of long chain n-3 polyunsaturated fatty acids (fish oil capsules) for 6 weeks
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 130
Study: 33461313

Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) therapy
Number of subjects: 129

Group type: COMPARATOR
Intervention: No intervention (control group: adults without OSA)
Number of subjects: 129
Study: 33461506

Group type: EXPERIMENTAL
Intervention: Cognitive training (CogniFit)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Entertainment gaming (SIMS 4)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 234
Study: 33461512

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 2
Study: 33463373

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (25 mg/m²)
Number of subjects: 0
Study: 33463384

Group type: EXPERIMENTAL
Intervention: Slow and deep breathing intervention, details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available.
Number of subjects: 0
Study: 33463536

Group type: EXPERIMENTAL
Intervention: Healthy twins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allergic twins
Number of subjects: 0
Study: 33463537

Group type: EXPERIMENTAL
Intervention: SEC23B-deficient T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T cells from patients with congenital dyserythropoietic anemia II (CDAII)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vivo rescue of murine KO by expression of Sec23a
Number of subjects: 0
Study: 33463535

Group type: EXPERIMENTAL
Intervention: Targeted immunomodulatory therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: FDA-approved drugs for IPF
Number of subjects: 0
Study: 33463542

Group type: EXPERIMENTAL
Intervention: Health-associated microbes from the Clostridia class enriched in healthy twins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Next-generation probiotic therapies
Number of subjects: 0
Study: 33463551

Group type: EXPERIMENTAL
Intervention: Early T follicular helper cell activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E2-specific MBCs from spontaneous resolvers
Number of subjects: 0

Group type: COMPARATOR
Intervention: E2-specific MBCs from chronically infected subjects
Number of subjects: 0
Study: 33463681

Group type: EXPERIMENTAL
Intervention: EHR-integrated digital health tools (checklist and video) administered on a mobile device via a patient portal or web-based survey at least 24 hours prior to anticipated discharge.
Number of subjects: 484
Study: 33464021

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV), Lamivudine (3TC), and Lopinavir/Ritonavir (LPV/r) syrup for 48 weeks according to WHO weight band dosing.
Number of subjects: 52
Study: 33464027

Group type: EXPERIMENTAL
Intervention: Multicolor confocal scanning laser ophthalmoscopy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Color fundus photography
Number of subjects: 30
Study: 33464147

Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab treatment
Number of subjects: 0
Study: 33464215

Group type: EXPERIMENTAL
Intervention: EaseVRx (8-week skills-based VR program)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sham VR (control condition)
Number of subjects: 180
Study: 33464575

Group type: EXPERIMENTAL
Intervention: Thrombolysis (with or without additional clot removal strategies)
Number of subjects: 1943
Study: 33464621

Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Entecavir
Number of subjects: 1800
Study: 33464953

Group type: EXPERIMENTAL
Intervention: Continuous-flow left ventricular assist devices (CF-LVADs)
Number of subjects: 12
Study: 33465022

Group type: EXPERIMENTAL
Intervention: Cannabis/cannabinoids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional treatments (e.g. opioids, NSAIDs)
Number of subjects: 0
Study: 33465034

Group type: EXPERIMENTAL
Intervention: TraceTogether contact tracing app
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Behavioral modifications due to the pandemic (e.g., using hand sanitizers, avoiding public transport, preferring outdoor venues)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Demographic and situational characteristics
Number of subjects: 505
Study: 33465252

Group type: EXPERIMENTAL
Intervention: PSMA-targeted radionuclide therapy (TRT)
Number of subjects: 215
Study: 33465704

Group type: EXPERIMENTAL
Intervention: Avapritinib
Number of subjects: 56
Study: 33466285

Group type: EXPERIMENTAL
Intervention: Endocannabinoidome (eCBome) subsets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictive regression models based on selected endocannabinoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Descriptive approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of quartiles
Number of subjects: 0
Study: 33467570

Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Entrectinib
Number of subjects: 0
Study: 33467875

Group type: EXPERIMENTAL
Intervention: First retrieval attempt
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: Second retrieval attempt
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: Third retrieval attempt
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: Successful reperfusion within the first 3 retrieval attempts
Number of subjects: 1225
Study: 33468262

Group type: EXPERIMENTAL
Intervention: Composite global symptom score for abdominal symptoms
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Abdominal tension
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Upper abdominal pain
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Abdominal discomfort
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Constipation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: EULAR Sjögren syndrome disease activity index score
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: EULAR Sjogren Syndrome Patient Reported Index (ESSPRI) symptom score
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 150
Study: 33468698

Group type: EXPERIMENTAL
Intervention: DNA vaccine pBI-11 targeting HPV16 and HPV18 E6 and E7 proteins
Number of subjects: 0

Group type: COMPARATOR
Intervention: DNA vaccine pBI-10.1 utilizing native viral sequences
Number of subjects: 0
Study: 33469058

Group type: EXPERIMENTAL
Intervention: P2Y12 G52T variant (TT group)
Number of subjects: 4489

Group type: COMPARATOR
Intervention: Other groups (GG and GT)
Number of subjects: 4489
Study: 33469259

Group type: EXPERIMENTAL
Intervention: OTX-101
Number of subjects: 745

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 745
Study: 33469316

Group type: EXPERIMENTAL
Intervention: Tezepelumab 70 mg Q4W
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg Q4W
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Tezepelumab 280 mg Q2W
Number of subjects: 550

Group type: COMPARATOR
Intervention: Placebo Q2W
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Tezepelumab (all doses)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 550
Study: 33469328

Group type: EXPERIMENTAL
Intervention: Insulin glargine biosimilar Ezelin (EZL)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Originator insulin glargine Lantus (LAN)
Number of subjects: 133
Study: 33469351

Group type: EXPERIMENTAL
Intervention: Active low-level laser therapy + moderate-intensity aerobic exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo low-level laser therapy + moderate-intensity aerobic exercise
Number of subjects: 60
Study: 33469439

Group type: EXPERIMENTAL
Intervention: COVID-19 care units (CCU)
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Non-COVID-19 care units (NCCU)
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: CCU + NCCU
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Physicians
Number of subjects: 1244
Study: 33469542

Group type: EXPERIMENTAL
Intervention: Abnormal chest imaging findings
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Low peripheral blood oxygen saturation
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Moderately-elevated body temperature
Number of subjects: 125

Group type: COMPARATOR
Intervention: Normal chest imaging findings
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Discharged after improvement
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Transferred for advanced care
Number of subjects: 125
Study: 33469662

Group type: EXPERIMENTAL
Intervention: Plasma diagnostic and prognostic biomarkers of cerebral cavernous angioma with symptomatic hemorrhage (CASH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrative combinations of plasma proteins and micro-ribonucleic acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advanced statistical and machine learning approaches
Number of subjects: 0
Study: 33469828

Group type: EXPERIMENTAL
Intervention: Persistently Gd-enhancing lesions (PE group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No enhancement (NE group)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Persistently Gd-enhancing lesions (PE group) in aquaporin-4-positive, first-attack, transverse myelitis or high-dose steroid treatment subgroup
Number of subjects: 41
Study: 33469845

Group type: EXPERIMENTAL
Intervention: GetActive-Fitbit program (10-week group program integrating mind-body skills, pain coping, and activity monitoring with Fitbit)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: GetActive-Fitbit program
Number of subjects: 4
Study: 33469852

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of autologous bone marrow-derived mesenchymal stem cells (MSCs) (1 × 10)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 2
Study: 33469905

Group type: EXPERIMENTAL
Intervention: POC-ECT with whole blood (WB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: POC-ECT with citrated blood (CB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: POC-ECT with citrated plasma (CP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: DTM assay
Number of subjects: 40
Study: 33470063

Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg/day
Number of subjects: 19
Study: 33470662

Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimizing time to antimicrobial therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Appropriate antibiotic choice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antimicrobial dosing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: De-escalation of therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimization of duration of antimicrobials
Number of subjects: 0
Study: 33470848

Group type: EXPERIMENTAL
Intervention: Telemedicine (tele-ED) consultation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non telemedicine patients
Number of subjects: 25
Study: 33470897

Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid topical application and 633 nm red light illumination
Number of subjects: 0
Study: 33470899

Group type: EXPERIMENTAL
Intervention: Telemedicine-facilitated palliative care consultations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard palliative care consultations (if applicable)
Number of subjects: 0
Study: 33470940

Group type: EXPERIMENTAL
Intervention: EVO Monitor (video game-based digital therapeutic)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard measures (Brief International Cognitive Assessment for Multiple Sclerosis, including SDMT and MS Functional Composite 4)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EVO Monitor performance
Number of subjects: 100
Study: 33470990

Group type: EXPERIMENTAL
Intervention: Guided physical activity increase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-hospital (pre/post dialysis) supervised exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Performance assessment only
Number of subjects: 0